Annual Cash & Cash Equivalents
$2.82 B
+$751.60 M+36.36%
31 December 2023
Summary:
Eli Lilly and Company annual cash & cash equivalents is currently $2.82 billion, with the most recent change of +$751.60 million (+36.36%) on 31 December 2023. During the last 3 years, it has fallen by -$838.50 million (-22.93%). LLY annual cash & cash equivalents is now -61.50% below its all-time high of $7.32 billion, reached on 31 December 2018.LLY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$3.37 B
+$145.40 M+4.51%
30 September 2024
Summary:
Eli Lilly and Company quarterly cash and cash equivalents is currently $3.37 billion, with the most recent change of +$145.40 million (+4.51%) on 30 September 2024. Over the past year, it has increased by +$988.20 million (+41.51%). LLY quarterly cash and cash equivalents is now -62.40% below its all-time high of $8.96 billion, reached on 30 September 2018.LLY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LLY Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +36.4% | +41.5% |
| 3 y3 years | -22.9% | -11.1% |
| 5 y5 years | -61.5% | +115.4% |
LLY Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -26.2% | +36.4% | -11.8% | +63.0% |
| 5 y | 5 years | -61.5% | +36.4% | -11.8% | +115.4% |
| alltime | all time | -61.5% | +772.6% | -62.4% | +1362.2% |
Eli Lilly And Company Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.37 B(+4.5%) |
| June 2024 | - | $3.22 B(+31.0%) |
| Mar 2024 | - | $2.46 B(-12.7%) |
| Dec 2023 | $2.82 B(+36.4%) | $2.82 B(+18.4%) |
| Sept 2023 | - | $2.38 B(-11.6%) |
| June 2023 | - | $2.69 B(-24.0%) |
| Mar 2023 | - | $3.55 B(+71.5%) |
| Dec 2022 | $2.07 B(-45.9%) | $2.07 B(-21.0%) |
| Sept 2022 | - | $2.62 B(-0.2%) |
| June 2022 | - | $2.62 B(+6.7%) |
| Mar 2022 | - | $2.46 B(-35.6%) |
| Dec 2021 | $3.82 B(+4.4%) | $3.82 B(+0.8%) |
| Sept 2021 | - | $3.79 B(+17.6%) |
| June 2021 | - | $3.22 B(+7.2%) |
| Mar 2021 | - | $3.00 B(-17.9%) |
| Dec 2020 | $3.66 B(+56.5%) | $3.66 B(+1.7%) |
| Sept 2020 | - | $3.60 B(+52.0%) |
| June 2020 | - | $2.37 B(+39.2%) |
| Mar 2020 | - | $1.70 B(-27.3%) |
| Dec 2019 | $2.34 B(-68.1%) | $2.34 B(+49.5%) |
| Sept 2019 | - | $1.56 B(-31.7%) |
| June 2019 | - | $2.29 B(+12.5%) |
| Mar 2019 | - | $2.04 B(-72.2%) |
| Dec 2018 | $7.32 B(+12.0%) | $7.32 B(-18.3%) |
| Sept 2018 | - | $8.96 B(+31.4%) |
| June 2018 | - | $6.82 B(+121.0%) |
| Mar 2018 | - | $3.08 B(-52.8%) |
| Dec 2017 | $6.54 B(+42.6%) | $6.54 B(+75.5%) |
| Sept 2017 | - | $3.72 B(+21.3%) |
| June 2017 | - | $3.07 B(+17.3%) |
| Mar 2017 | - | $2.62 B(-42.9%) |
| Dec 2016 | $4.58 B(+25.0%) | $4.58 B(+31.3%) |
| Sept 2016 | - | $3.49 B(+7.8%) |
| June 2016 | - | $3.24 B(+40.3%) |
| Mar 2016 | - | $2.31 B(-37.1%) |
| Dec 2015 | $3.67 B(-5.3%) | $3.67 B(+13.2%) |
| Sept 2015 | - | $3.24 B(-2.3%) |
| June 2015 | - | $3.32 B(+8.2%) |
| Mar 2015 | - | $3.06 B(-20.8%) |
| Dec 2014 | $3.87 B(+1.1%) | $3.87 B(+22.3%) |
| Sept 2014 | - | $3.17 B(-15.9%) |
| June 2014 | - | $3.77 B(-3.1%) |
| Mar 2014 | - | $3.89 B(+1.5%) |
| Dec 2013 | $3.83 B(-4.7%) | $3.83 B(-12.3%) |
| Sept 2013 | - | $4.37 B(+15.4%) |
| June 2013 | - | $3.79 B(-3.8%) |
| Mar 2013 | - | $3.94 B(-2.0%) |
| Dec 2012 | $4.02 B(-32.1%) | $4.02 B(-24.4%) |
| Sept 2012 | - | $5.32 B(+22.4%) |
| June 2012 | - | $4.35 B(+5.4%) |
| Mar 2012 | - | $4.12 B(-30.4%) |
| Dec 2011 | $5.92 B(-1.2%) | $5.92 B(-10.2%) |
| Sept 2011 | - | $6.60 B(+7.9%) |
| June 2011 | - | $6.11 B(-6.0%) |
| Mar 2011 | - | $6.51 B(+8.6%) |
| Dec 2010 | $5.99 B(+34.3%) | $5.99 B(+16.1%) |
| June 2010 | - | $5.16 B(+9.3%) |
| Mar 2010 | - | $4.73 B(+5.9%) |
| Dec 2009 | $4.46 B(-18.8%) | $4.46 B(+16.0%) |
| Sept 2009 | - | $3.85 B(+15.8%) |
| June 2009 | - | $3.32 B(+0.3%) |
| Mar 2009 | - | $3.31 B(-39.7%) |
| Dec 2008 | $5.50 B(+70.7%) | $5.50 B(+26.3%) |
| Sept 2008 | - | $4.35 B(+51.8%) |
| June 2008 | - | $2.87 B(-8.8%) |
| Mar 2008 | - | $3.15 B(-2.3%) |
| Dec 2007 | $3.22 B(+3.6%) | $3.22 B(+29.1%) |
| Sept 2007 | - | $2.50 B(+12.4%) |
| June 2007 | - | $2.22 B(-10.9%) |
| Mar 2007 | - | $2.49 B(-19.9%) |
| Dec 2006 | $3.11 B | $3.11 B(+43.3%) |
| Sept 2006 | - | $2.17 B(-18.7%) |
| June 2006 | - | $2.67 B(+8.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2006 | - | $2.46 B(-18.2%) |
| Dec 2005 | $3.01 B(-44.0%) | $3.01 B(-39.5%) |
| Sept 2005 | - | $4.97 B(+7.1%) |
| June 2005 | - | $4.64 B(-17.2%) |
| Mar 2005 | - | $5.61 B(+4.5%) |
| Dec 2004 | $5.37 B(+94.7%) | $5.37 B(+108.2%) |
| Sept 2004 | - | $2.58 B(+7.5%) |
| June 2004 | - | $2.40 B(-0.6%) |
| Mar 2004 | - | $2.41 B(-12.5%) |
| Dec 2003 | $2.76 B(+41.6%) | $2.76 B(-5.5%) |
| Sept 2003 | - | $2.92 B(+43.1%) |
| June 2003 | - | $2.04 B(-7.6%) |
| Mar 2003 | - | $2.20 B(+13.3%) |
| Dec 2002 | $1.95 B(-28.0%) | $1.95 B(-30.2%) |
| Sept 2002 | - | $2.79 B(-8.7%) |
| June 2002 | - | $3.05 B(+5.9%) |
| Mar 2002 | - | $2.88 B(+6.6%) |
| Dec 2001 | $2.70 B(-34.3%) | $2.70 B(+2.1%) |
| Sept 2001 | - | $2.65 B(-11.0%) |
| June 2001 | - | $2.97 B(-8.0%) |
| Mar 2001 | - | $3.23 B(-21.5%) |
| Dec 2000 | $4.11 B(+11.2%) | $4.11 B(+32.0%) |
| Sept 2000 | - | $3.12 B(-7.5%) |
| June 2000 | - | $3.37 B(-11.3%) |
| Mar 2000 | - | $3.80 B(+2.6%) |
| Dec 1999 | $3.70 B(+147.4%) | $3.70 B(+12.4%) |
| Sept 1999 | - | $3.29 B(+62.0%) |
| June 1999 | - | $2.03 B(-15.5%) |
| Mar 1999 | - | $2.40 B(+60.8%) |
| Dec 1998 | $1.50 B(-23.2%) | $1.50 B(-3.1%) |
| Sept 1998 | - | $1.54 B(+17.4%) |
| June 1998 | - | $1.32 B(+4.0%) |
| Mar 1998 | - | $1.26 B(-35.1%) |
| Dec 1997 | $1.95 B(+139.3%) | $1.95 B(+29.5%) |
| Sept 1997 | - | $1.50 B(-18.8%) |
| June 1997 | - | $1.85 B(+77.8%) |
| Mar 1997 | - | $1.04 B(+28.1%) |
| Dec 1996 | $813.70 M(-18.6%) | $813.70 M(+10.2%) |
| Sept 1996 | - | $738.10 M(-34.4%) |
| June 1996 | - | $1.13 B(+25.2%) |
| Mar 1996 | - | $898.40 M(-10.1%) |
| Dec 1995 | $999.50 M(+86.2%) | $999.50 M(+2.4%) |
| Sept 1995 | - | $976.20 M(-1.4%) |
| June 1995 | - | $989.70 M(+1.1%) |
| Mar 1995 | - | $978.80 M(+82.3%) |
| Dec 1994 | $536.90 M(-0.5%) | $536.90 M(-46.3%) |
| Sept 1994 | - | $999.60 M(+41.4%) |
| June 1994 | - | $706.80 M(+16.8%) |
| Mar 1994 | - | $604.90 M(+12.1%) |
| Dec 1993 | $539.60 M(+24.8%) | $539.60 M(-15.2%) |
| Sept 1993 | - | $636.10 M(+42.1%) |
| June 1993 | - | $447.70 M(-24.7%) |
| Mar 1993 | - | $594.60 M(+37.5%) |
| Dec 1992 | $432.40 M(-9.8%) | $432.40 M(+21.7%) |
| Sept 1992 | - | $355.20 M(-16.5%) |
| June 1992 | - | $425.40 M(+21.1%) |
| Mar 1992 | - | $351.30 M(-26.7%) |
| Dec 1991 | $479.20 M(+36.8%) | $479.20 M(+63.3%) |
| Sept 1991 | - | $293.50 M(+27.4%) |
| June 1991 | - | $230.40 M(-23.9%) |
| Mar 1991 | - | $302.80 M(-13.5%) |
| Dec 1990 | $350.20 M(+8.4%) | $350.20 M(-29.1%) |
| Sept 1990 | - | $494.00 M(+7.6%) |
| June 1990 | - | $459.10 M(+9.5%) |
| Mar 1990 | - | $419.30 M(+29.8%) |
| Dec 1989 | $323.00 M(-57.6%) | $323.00 M(-45.0%) |
| Sept 1989 | - | $587.40 M(+2.6%) |
| June 1989 | - | $572.40 M(-24.8%) |
| Dec 1988 | $761.50 M(-26.1%) | $761.50 M(-26.1%) |
| Dec 1987 | $1.03 B(+112.1%) | $1.03 B(+112.1%) |
| Dec 1986 | $486.00 M(+19.7%) | $486.00 M(+19.7%) |
| Dec 1985 | $406.10 M(-8.8%) | $406.10 M(-8.8%) |
| Dec 1984 | $445.30 M | $445.30 M |
FAQ
- What is Eli Lilly and Company annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Eli Lilly and Company?
- What is Eli Lilly and Company annual cash & cash equivalents year-on-year change?
- What is Eli Lilly and Company quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Eli Lilly and Company?
- What is Eli Lilly and Company quarterly cash and cash equivalents year-on-year change?
What is Eli Lilly and Company annual cash & cash equivalents?
The current annual cash & cash equivalents of LLY is $2.82 B
What is the all time high annual cash & cash equivalents for Eli Lilly and Company?
Eli Lilly and Company all-time high annual cash & cash equivalents is $7.32 B
What is Eli Lilly and Company annual cash & cash equivalents year-on-year change?
Over the past year, LLY annual cash & cash equivalents has changed by +$751.60 M (+36.36%)
What is Eli Lilly and Company quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LLY is $3.37 B
What is the all time high quarterly cash and cash equivalents for Eli Lilly and Company?
Eli Lilly and Company all-time high quarterly cash and cash equivalents is $8.96 B
What is Eli Lilly and Company quarterly cash and cash equivalents year-on-year change?
Over the past year, LLY quarterly cash and cash equivalents has changed by +$988.20 M (+41.51%)